Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.


Last reviewed on RxList: 5/1/2020
Endari Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Endari?

Endari (L-glutamine oral powder) is an amino acid indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

What Are Side Effects of Endari?

Common side effects of Endari include:

Dosage for Endari

The dose of Endari is 5 to 15 grams orally, twice daily based on body weight. Each dose of Endari should be mixed in 8 oz. (240 mL) of cold or room temperature beverage or 4 to 6 oz. of food before ingestion.

What Drugs, Substances, or Supplements Interact with Endari?

Endari may interact with other drugs. Tell your doctor all medications and supplements you use.

Endari During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Endari; it is unknown how it may affect a fetus. It is unknown if Endari passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Endari (L-glutamine oral powder) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Anemia Symptoms and Signs, Types, Treatment and Causes See Slideshow
Endari Professional Information


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to Endari in 187 patients, including 136 exposed for 6 months and 109 exposed for ≥1 year. Endari was studied in 2 placebo-controlled clinical trials (a phase 3 study, n=230 and a phase 2 study, n=70). In these trials, patients with sickle cell anemia or sickle β0-thalassemia were randomized to receive Endari (n=187) or placebo (n=111) orally twice daily for 48 weeks followed by 3 weeks of tapering. Both studies included pediatric and adult patients (5-58 years of age) and 54% were female. The majority of patients were black (97.3%), had a diagnosis of sickle cell anemia (89.9%) and were receiving hydroxyurea at baseline (63.4%).

Treatment discontinuation due to adverse reactions was reported in 2.7% (n=5) of patients receiving Endari. These adverse reactions included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

Serious adverse reactions were reported in both treatment groups, more frequently in the placebo group, and were consistent with the underlying disease.

Three deaths (3/187=1.6%) occurred during the study in the Endari treatment group as compared to none in the placebo treatment group. None of the deaths were considered to be related to Endari treatment. Adverse reactions occurring in greater than 10% of patients treated with Endari are shown in Table 2 below.

Table 2: Adverse Reactions Occurring at an Incidence > 10% in Clinical Studies of Endari

Adverse reaction Endari
N = 187 (%)
N = 111 (%)
Constipation 21 18
Nausea 19 14
Headache 18 15
Abdominal Pain1 17 16
Cough 16 14
Pain in extremity 13 7
Back pain 12 5
Chest pain 12 8
1Abdominal pain = abdominal pain and abdominal pain, upper

Read the entire FDA prescribing information for Endari (L-glutamine Oral Powder)


What is hemophilia? See Answer
Related Resources for Endari

Related Drugs

© Endari Patient Information is supplied by Cerner Multum, Inc. and Endari Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors